(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Investigate Something else for Less: Financial plan Travel Objections - 2Hoist Your Style: Famous Hairdos for Ladies
- 3This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- 4Instructions to Pick the Ideal SUV Size for Seniors
- 5What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 6 Fun Urban areas For Seniors To Travel
- What loving-kindness meditation is and how to practice it in the new year
- Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- Focus on Yourself: Wellbeing and Taking care of oneself Practices
- Pick Your #1 Kind Of Treat
- New Year's Eve Live: Nashville's Big Bash: How to watch the star-studded country music special live
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
